glp 1 ms The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review GLP-1 Doctor-Managed Weight Loss Marlboro,
Description
Still a bit too early to tell on that question
In Phase 1 and 2a clinical trials, once-daily subcutaneous injections of RG7697 (0.252.5 mg) for 14 days in 56 patients with T2DM and 1.8 mg of RG7697 for 12 weeks in patients with T2DM who were poorly responsive to metformin reduced body weight and improved glycemic control
Am J Clin Nutr 51(2):241247
This kind of visual in an ad by a pharma would be subject to rigorous discussion
Improved metabolic health Better blood sugar control, reduced insulin resistance, less inflammation
